It is time to define an organizational model for the prevention and management of infections along the surgical pathway: a worldwide cross-sectional survey.
Author
Sartelli, MassimoLabricciosa, Francesco M
Coccolini, Federico
Coimbra, Raul
Abu-Zidan, Fikri M
Ansaloni, Luca
Al-Hasan, Majdi N
Ansari, Shamshul
Barie, Philip S
Caínzos, Miguel Angel
Ceresoli, Marco
Chiarugi, Massimo
Claridge, Jeffrey A
Cicuttin, Enrico
Dellinger, Evan Patchen
Fry, Donald E
Guirao, Xavier
Hardcastle, Timothy Craig
Hecker, Andreas
Leppäniemi, Ari K
Litvin, Andrey
Marwah, Sanjay
Maseda, Emilio
Mazuski, John E
Memish, Ziad Ahmed
Kirkpatrick, Andrew W
Pagani, Leonardo
Podda, Mauro
Rasa, Huseyin Kemal
Sakakushev, Boris E
Sawyer, Robert G
Tumietto, Fabio
Xiao, Yonghong
Aboubreeg, Wedad Faraj
Adamou, Harissou
Akhmeteli, Lali
Akin, Emrah
Alberio, Maria Grazia
Alconchel, Felipe
Magagi, Ibrahim Amadou
Araúz, Ana Belén
Argenio, Giulio
Atanasov, Boyko C
Atici, Semra Demirli
Awad, Selmy Sabry
Baili, Efstratia
Bains, Lovenish
Bala, Miklosh
Baraket, Oussama
Baral, Suman
Belskii, Vladislav A
Benboubker, Moussa
Ben-Ishay, Offir
Bordoni, Pierpaolo
Boumédiène, Abdalia
Brisinda, Giuseppe
Cavazzuti, Laura
Chandy, Sujith J
Chiarello, Maria Michela
Cillara, Nicola
Clarizia, Guglielmo
Cocuz, Maria-Elena
Cocuz, Iuliu Gabriel
Conti, Luigi
Coppola, Raffaella
Cui, Yunfeng
Czepiel, Jacek
D'Acapito, Fabrizio
Damaskos, Dimitrios
Das, Koray
De Simone, Belinda
Delibegovic, Samir
Demetrashvili, Zaza
Detanac, Dzemail S
Dhingra, Sameer
Di Bella, Stefano
Dimitrov, Evgeni N
Dogjani, Agron
D'Oria, Mario
Dumitru, Irina Magdalena
Elmangory, Mutasim M
Enciu, Octavian
Fantoni, Massimo
Filipescu, Daniela
Fleres, Francesco
Foghetti, Domitilla
Fransvea, Pietro
Gachabayov, Mahir
Galeiras, Rita
Gattuso, Gianni
Ghannam, Wagih M
Ghisetti, Valeria
Giraudo, Giorgio
Gonfa, Kebebe Bekele
Gonullu, Emre
Hamad, Yousif Tag Elsir Y
Hecker, Matthias
Isik, Arda
Ismail, Nizar
Ismail, Azzain
Jain, Sumita Agarwal
Kanj, Souha S
Kapoor, Garima
Karaiskos, Ilias
Kavalakat, Alfie J
Kenig, Jakub
Khamis, Faryal
Khokha, Vladimir
Kiguba, Ronald
Kim, Jae Il
Kobe, Yoshiro
Kok, Kenneth Yuh Yen
Kovacevic, Bojan M
Kryvoruchko, Igor Andreevich
Kuriyama, Akira
Landaluce-Olavarria, Aitor
Lasithiotakis, Konstantinos
Lohsiriwat, Varut
Lostoridis, Eftychios
Luppi, Davide
Vega, Gustavo Miguel Machain
Maegele, Marc
Marinis, Athanasios
Martines, Gennaro
Martínez-Pérez, Aleix
Massalou, Damien
Mesina, Cristian
Metan, Gökhan
Miranda-Novales, María Guadalupe
Mishra, Shyam Kumar
Mohamed, Mohaned Ibrahim Hussein
Mohamedahmed, Ali Yasen Y
Mora-Guzmán, Ismael
Mulita, Francesk
Musina, Ana-Maria
Navsaria, Pradeep H
Negoi, Ionut
Nita, Gabriela Elisa
O'Connor, Donal B
Ordoñez, Carlos Alberto
Pantalone, Desiré
Panyko, Arpád
Papadopoulos, Aristeidis
Pararas, Nikolaos
Pata, Francesco
Patel, Tapan
Pellino, Gianluca
Perra, Teresa
Perrone, Gennaro
Pesce, Antonio
Pintar, Tadeja
Popivanov, Georgi Ivanov
Porcu, Alberto
Quiodettis, Martha Alexa
Rahim, Razrim
Mitul, Ashrarur Rahman
Reichert, Martin
Rems, Miran
Campbell, Glendee Yolande Reynolds
Rocha-Pereira, Nuno
Rodrigues, Gabriel
Villamil, Gustavo Eduardo Roncancio
Rossi, Stefano
Sall, Ibrahima
Kafil, Hossein Samadi
Sasia, Diego
Seni, Jeremiah
Seretis, Charalampos
Serradilla-Martín, Mario
Shelat, Vishal G
Siribumrungwong, Boonying
Slavchev, Mihail
Solaini, Leonardo
Tan, Boun Kim
Tarasconi, Antonio
Tartaglia, Dario
Toma, Elena Adelina
Tomadze, Gia
Toro, Adriana
Tovani-Palone, Marcos Roberto
van Goor, Harry
Vasilescu, Alin
Vereczkei, Andras
Veroux, Massimiliano
Weckmann, Sergio Alberto
Widmer, Lukas Werner
Yahya, AliIbrahim
Zachariah, Sanoop K
Zakaria, Andee Dzulkarnaen
Zubareva, Nadezhda
Zuidema, Wietse P
Di Carlo, Isidoro
Cortese, Francesco
Baiocchi, Gian Luca
Maier, Ronald V
Catena, Fausto
Publication date
2022-03-17Subject
Surgery
Metadata
Show full item recordAbstract
Background: The objectives of the study were to investigate the organizational characteristics of acute care facilities worldwide in preventing and managing infections in surgery; assess participants' perception regarding infection prevention and control (IPC) measures, antibiotic prescribing practices, and source control; describe awareness about the global burden of antimicrobial resistance (AMR) and IPC measures; and determine the role of the Coronavirus Disease 2019 pandemic on said awareness. ethods: A cross-sectional web-based survey was conducted contacting 1432 health care workers (HCWs) belonging to a mailing list provided by the Global Alliance for Infections in Surgery. The self-administered questionnaire was developed by a multidisciplinary team. The survey was open from May 22, 2021, and June 22, 2021. Three reminders were sent, after 7, 14, and 21 days. Results: Three hundred four respondents from 72 countries returned a questionnaire, with an overall response rate of 21.2%. Respectively, 90.4% and 68.8% of participants stated their hospital had a multidisciplinary IPC team or a multidisciplinary antimicrobial stewardship team. Local protocols for antimicrobial therapy of surgical infections and protocols for surgical antibiotic prophylaxis were present in 76.6% and 90.8% of hospitals, respectively. In 23.4% and 24.0% of hospitals no surveillance systems for surgical site infections and no monitoring systems of used antimicrobials were implemented. Patient and family involvement in IPC management was considered to be slightly or not important in their hospital by the majority of respondents (65.1%). Awareness of the global burden of AMR among HCWs was considered very important or important by 54.6% of participants. The COVID-19 pandemic was considered by 80.3% of respondents as a very important or important factor in raising HCWs awareness of the IPC programs in their hospital. Based on the survey results, the authors developed 15 statements for several questions regarding the prevention and management of infections in surgery. The statements may be the starting point for designing future evidence-based recommendations. Conclusion: Adequacy of prevention and management of infections in acute care facilities depends on HCWs behaviours and on the organizational characteristics of acute health care facilities to support best practices and promote behavioural change. Patient involvement in the implementation of IPC is still little considered. A debate on how operationalising a fundamental change to IPC, from being solely the HCWs responsibility to one that involves a collaborative relationship between HCWs and patients, should be opened.Citation
Sartelli M, Labricciosa FM, Coccolini F, Coimbra R, Abu-Zidan FM, Ansaloni L, Al-Hasan MN, Ansari S, Barie PS, Caínzos MA, Ceresoli M, Chiarugi M, Claridge JA, Cicuttin E, Dellinger EP, Fry DE, Guirao X, Hardcastle TC, Hecker A, Leppäniemi AK, Litvin A, Marwah S, Maseda E, Mazuski JE, Memish ZA, Kirkpatrick AW, Pagani L, Podda M, Rasa HK, Sakakushev BE, Sawyer RG, Tumietto F, Xiao Y, Aboubreeg WF, Adamou H, Akhmeteli L, Akin E, Alberio MG, Alconchel F, Magagi IA, Araúz AB, Argenio G, Atanasov BC, Atici SD, Awad SS, Baili E, Bains L, Bala M, Baraket O, Baral S, Belskii VA, Benboubker M, Ben-Ishay O, Bordoni P, Boumédiène A, Brisinda G, Cavazzuti L, Chandy SJ, Chiarello MM, Cillara N, Clarizia G, Cocuz ME, Cocuz IG, Conti L, Coppola R, Cui Y, Czepiel J, D'Acapito F, Damaskos D, Das K, De Simone B, Delibegovic S, Demetrashvili Z, Detanac DS, Dhingra S, Di Bella S, Dimitrov EN, Dogjani A, D'Oria M, Dumitru IM, Elmangory MM, Enciu O, Fantoni M, Filipescu D, Fleres F, Foghetti D, Fransvea P, Gachabayov M, Galeiras R, Gattuso G, Ghannam WM, Ghisetti V, Giraudo G, Gonfa KB, Gonullu E, Hamad YTEY, Hecker M, Isik A, Ismail N, Ismail A, Jain SA, Kanj SS, Kapoor G, Karaiskos I, Kavalakat AJ, Kenig J, Khamis F, Khokha V, Kiguba R, Kim JI, Kobe Y, Kok KYY, Kovacevic BM, Kryvoruchko IA, Kuriyama A, Landaluce-Olavarria A, Lasithiotakis K, Lohsiriwat V, Lostoridis E, Luppi D, Vega GMM, Maegele M, Marinis A, Martines G, Martínez-Pérez A, Massalou D, Mesina C, Metan G, Miranda-Novales MG, Mishra SK, Mohamed MIH, Mohamedahmed AYY, Mora-Guzmán I, Mulita F, Musina AM, Navsaria PH, Negoi I, Nita GE, O'Connor DB, Ordoñez CA, Pantalone D, Panyko A, Papadopoulos A, Pararas N, Pata F, Patel T, Pellino G, Perra T, Perrone G, Pesce A, Pintar T, Popivanov GI, Porcu A, Quiodettis MA, Rahim R, Mitul AR, Reichert M, Rems M, Campbell GYR, Rocha-Pereira N, Rodrigues G, Villamil GER, Rossi S, Sall I, Kafil HS, Sasia D, Seni J, Seretis C, Serradilla-Martín M, Shelat VG, Siribumrungwong B, Slavchev M, Solaini L, Tan BK, Tarasconi A, Tartaglia D, Toma EA, Tomadze G, Toro A, Tovani-Palone MR, van Goor H, Vasilescu A, Vereczkei A, Veroux M, Weckmann SA, Widmer LW, Yahya A, Zachariah SK, Zakaria AD, Zubareva N, Zuidema WP, Di Carlo I, Cortese F, Baiocchi GL, Maier RV, Catena F. It is time to define an organizational model for the prevention and management of infections along the surgical pathway: a worldwide cross-sectional survey. World J Emerg Surg. 2022 Mar 17;17(1):17. doi: 10.1186/s13017-022-00420-4Type
ArticlePMID
35300731Publisher
BMCae974a485f413a2113503eed53cd6c53
10.1186/s13017-022-00420-4
Scopus Count
Related items
Showing items related by title, author, creator and subject.
-
Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.Goodyear, Carl S; Patel, Amit; Patel, Amit; Barnes, Eleanor; Barnes, Eleanor; Willicombe, Michelle; Willicombe, Michelle; Siebert, Stefan; de Silva, Thushan I; de Silva, Thushan I; et al. (Elsevier, 2024-05-08)Background: The humoral and T-cell responses to booster COVID-19 vaccine types in multidisease immunocompromised individuals who do not generate adequate antibody responses to two COVID-19 vaccine doses, is not fully understood. The OCTAVE DUO trial aimed to determine the value of third vaccinations in a wide range of patients with primary and secondary immunodeficiencies. Methods: OCTAVE-DUO was a prospective, open-label, multicentre, randomised, controlled, phase 3 trial investigating humoral and T-cell responses in patients who are immunocompromised following a third vaccine dose with BNT162b2 or mRNA-1273, and of NVX-CoV2373 for those with lymphoid malignancies. We recruited patients who were immunocompromised from 11 UK hospitals, aged at least 18 years, with previous sub-optimal responses to two doses of SARS-CoV-2 vaccine. Participants were randomly assigned 1:1 (1:1:1 for those with lymphoid malignancies), stratified by disease, previous vaccination type, and anti-spike antibody response following two doses. Individuals with lived experience of immune susceptibility were involved in the study design and implementation. The primary outcome was vaccine-specific immunity defined by anti-SARS-CoV-2 spike antibodies (Roche Diagnostics UK and Ireland, Burgess Hill, UK) and T-cell responses (Oxford Immunotec, Abingdon, UK) before and 21 days after the third vaccine dose analysed by a modified intention-to-treat analysis. The trial is registered with the ISRCTN registry, ISRCTN 15354495, and the EU Clinical Trials Register, EudraCT 2021-003632-87, and is complete. Findings: Between Aug 4, 2021 and Mar 31, 2022, 804 participants across nine disease cohorts were randomly assigned to receive BNT162b2 (n=377), mRNA-1273 (n=374), or NVX-CoV2373 (n=53). 356 (45%) of 789 participants were women, 433 (55%) were men, and 659 (85%) of 775 were White. Anti-SARS-CoV-2 spike antibodies measured 21 days after the third vaccine dose were significantly higher than baseline pre-third dose titres in the modified intention-to-treat analysis (median 1384 arbitrary units [AU]/mL [IQR 4·3-7990·0] compared with median 11·5 AU/mL [0·4-63·1]; p<0·001). Of participants who were baseline low responders, 380 (90%) of 423 increased their antibody concentrations to more than 400 AU/mL. Conversely, 166 (54%) of 308 baseline non-responders had no response after the third dose. Detectable T-cell responses following the third vaccine dose were seen in 494 (80%) of 616 participants. There were 24 serious adverse events (BNT612b2 eight [33%] of 24, mRNA-1273 12 [50%], NVX-CoV2373 four [17%]), two (8%) of which were categorised as vaccine-related. There were seven deaths (1%) during the trial, none of which were vaccine-related. Interpretation: A third vaccine dose improved the serological and T-cell response in the majority of patients who are immunocompromised. Individuals with chronic renal disease, lymphoid malignancy, on B-cell targeted therapies, or with no serological response after two vaccine doses are at higher risk of poor response to a third vaccine dose. Funding: Medical Research Council, Blood Cancer UK.
-
30-Day morbidity and mortality of bariatric surgery during the COVID-19 pandemic: a multinational cohort study of 7704 patients from 42 countries.Singhal, Rishi; Ludwig, Christian; Rudge, Gavin; Gkoutos, Georgios V; Tahrani, Abd; Mahawar, Kamal; Pędziwiatr, Michał; Major, Piotr; Zarzycki, Piotr; Pantelis, Athanasios; et al. (Springer, 2021-07-30)Background: There are data on the safety of cancer surgery and the efficacy of preventive strategies on the prevention of postoperative symptomatic COVID-19 in these patients. But there is little such data for any elective surgery. The main objectives of this study were to examine the safety of bariatric surgery (BS) during the coronavirus disease 2019 (COVID-19) pandemic and to determine the efficacy of perioperative COVID-19 protective strategies on postoperative symptomatic COVID-19 rates. Methods: We conducted an international cohort study to determine all-cause and COVID-19-specific 30-day morbidity and mortality of BS performed between 01/05/2020 and 31/10/2020. Results: Four hundred ninety-nine surgeons from 185 centres in 42 countries provided data on 7704 patients. Elective primary BS (n = 7084) was associated with a 30-day morbidity of 6.76% (n = 479) and a 30-day mortality of 0.14% (n = 10). Emergency BS, revisional BS, insulin-treated type 2 diabetes, and untreated obstructive sleep apnoea were associated with increased complications on multivariable analysis. Forty-three patients developed symptomatic COVID-19 postoperatively, with a higher risk in non-whites. Preoperative self-isolation, preoperative testing for SARS-CoV-2, and surgery in institutions not concurrently treating COVID-19 patients did not reduce the incidence of postoperative COVID-19. Postoperative symptomatic COVID-19 was more likely if the surgery was performed during a COVID-19 peak in that country. Conclusions: BS can be performed safely during the COVID-19 pandemic with appropriate perioperative protocols. There was no relationship between preoperative testing for COVID-19 and self-isolation with symptomatic postoperative COVID-19. The risk of postoperative COVID-19 risk was greater in non-whites or if BS was performed during a local peak.
-
Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe.Kroese, Tiuri E; van Hillegersberg, Richard; Schoppmann, Sebastian; Deseyne, Pieter R A J; Nafteux, Philippe; Obermannova, Radka; Nordsmark, Marianne; Pfeiffer, Per; Hawkins, Maria A; Smyth, Elizabeth; et al. (Elsevier Science, 2022-02-05)Background: Consensus about the definition and treatment of oligometastatic oesophagogastric cancer is lacking. Objective: To assess the definition and treatment of oligometastatic oesophagogastric cancer across multidisciplinary tumour boards (MDTs) in Europe. Material and methods: European expert centers (n = 49) were requested to discuss 15 real-life cases in their MDT with at least a medical, surgical, and radiation oncologist present. The cases varied in terms of location and number of metastases, histology, timing of detection (i.e. synchronous versus metachronous), primary tumour treatment status, and response to systemic therapy. The primary outcome was the agreement in the definition of oligometastatic disease at diagnosis and after systemic therapy. The secondary outcome was the agreement in treatment strategies. Treatment strategies for oligometastatic disease were categorised into upfront local treatment (i.e. metastasectomy or stereotactic radiotherapy), systemic therapy followed by restaging to consider local treatment or systemic therapy alone. The agreement across MDTs was scored to be either absent/poor (<50%), fair (50%-75%), or consensus (≥75%). Results: A total of 47 MDTs across 16 countries fully discussed the cases (96%). Oligometastatic disease was considered in patients with 1-2 metastases in either the liver, lung, retroperitoneal lymph nodes, adrenal gland, soft tissue or bone (consensus). At follow-up, oligometastatic disease was considered after a median of 18 weeks of systemic therapy when no progression or progression in size only of the oligometastatic lesion(s) was seen (consensus). If at restaging after a median of 18 weeks of systemic therapy the number of lesions progressed, this was not considered as oligometastatic disease (fair agreement). There was no consensus on treatment strategies for oligometastatic disease. Conclusion: A broad consensus on definitions of oligometastatic oesophagogastric cancer was found among MDTs of oesophagogastric cancer expert centres in Europe. However, high practice variability in treatment strategies exists.